Ayesha N Shajahan-Haq

List of Publications by Year
in descending order

59 papers	7,090 citations	218677 26 h-index	233421 45 g-index
61 all docs	61 docs citations	61 times ranked	17706 citing authors

#	Article	IF	Citations
1	Caveolin-1 controls mitochondrial damage and ROS production by regulating fission - fusion dynamics and mitophagy. Redox Biology, 2022, 52, 102304.	9.0	32
2	Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. Cancer, 2021, 127, 3622-3630.	4.1	8
3	Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors. Frontiers in Oncology, 2021, 11, 681530.	2.8	15
4	Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 12292.	4.1	31
5	Mathematical modelling of breast cancer cells in response to endocrine therapy and Cdk4/6 inhibition. Journal of the Royal Society Interface, 2020, 17, 20200339.	3.4	12
6	Inhibition of DNA Repair Pathways and Induction of ROS Are Potential Mechanisms of Action of the Small Molecule Inhibitor BOLD-100 in Breast Cancer. Cancers, 2020, 12, 2647.	3.7	25
7	Abstract P3-09-14: Regulation of gene expression and DNA methylation with cytotoxic T lymphocytes evaluation in subtypes of breast cancers. , 2020, , .		0
8	Abstract P1-19-20: Safety of palbociclib in African American women with hormone receptor positive HER2 negative advanced breast cancer and benign ethnic neutropenia: PALINA study. , 2020, , .		0
9	Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer. Frontiers in Oncology, 2019, 9, 686.	2.8	41
10	Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Research and Treatment, 2019, 175, 595-603.	2.5	106
11	Abstract 674: Predicting cellular response to therapy in breast cancer using mathematical modeling. , 2019, , .		0
12	Dielectrophoretic properties distinguish responses to estrogen and fulvestrant in breast cancer cells. Sensors and Actuators B: Chemical, 2018, 277, 186-194.	7.8	3
13	PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. Contemporary Clinical Trials Communications, 2018, 10, 190-192.	1.1	7
14	Promoting Scientistâ€“Advocate Collaborations in Cancer Research: Why and How. Cancer Research, 2018, 78, 5723-5728.	0.9	27
15	CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities. , 2018, 191, 65-73.		50
16	SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function.. Journal of Clinical Oncology, 2018, 36, 1038-1038.	1.6	7
17	Abstract 2862: Inhibition of DNA repair pathways in breast cancer is a potential mechanism of action of IT-139. , 2018, , .		0
18	Breast cancer cell obatoclax response characterization using passivatedâ€electrode insulatorâ€based dielectrophoresis. Electrophoresis, 2017, 38, 1988-1995.	2.4	23

#	Article	IF	Citations
19	PSSV: a novel pattern-based probabilistic approach for somatic structural variation identification. Bioinformatics, 2017, 33, 177-183.	4.1	5
20	EGR1 regulates cellular metabolism and survival in endocrine resistant breast cancer. Oncotarget, 2017, 8, 96865-96884.	1.8	29
21	MYC-Driven Pathways in Breast Cancer Subtypes. Biomolecules, 2017, 7, 53.	4.0	152
22	Abstract 430: Combination of CB-839 and everolimus is effective in inhibiting growth of endocrine resistant breast cancer in vivo. , 2017, , .		0
23	Systems Approaches to Cancer Biology. Cancer Research, 2016, 76, 6774-6777.	0.9	26
24	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
25	ChIP-BIT: Bayesian inference of target genes using a novel joint probabilistic model of ChIP-seq profiles. Nucleic Acids Research, 2016, 44, e65-e65.	14.5	15
26	Abstract 1508: Integration of transcriptomic and metabolomic data reveals a central role for EGR1 in regulating survival and cellular metabolism in endocrine-resistant breast cancer. , 2016, , .		1
27	Caveolin-1 regulates cancer cell metabolism via scavenging Nrf2 and suppressing MnSOD-driven glycolysis. Oncotarget, 2016, 7, 308-322.	1.8	42
28	Dynamic Modeling of the Interaction Between Autophagy and Apoptosis in Mammalian Cells. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 263-272.	2.5	67
29	Application of Metabolomics in Drug Resistant Breast Cancer Research. Metabolites, 2015, 5, 100-118.	2.9	50
30	BMRF-Net: a software tool for identification of protein interaction subnetworks by a bagging Markov random field-based method. Bioinformatics, 2015, 31, 2412-2414.	4.1	30
31	Interferon Regulatory Factor-1 Signaling Regulates the Switch between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate. Cancer Research, 2015, 75, 1046-1055.	0.9	31
32	Integrating Proteotoxic Stress Response Pathways for Induction of Cell Death in Cancer Cells: Molecular Mechanisms and Therapeutic Opportunities. , 2015, , 183-202.		0
33	Abstract 1258: The unfolded protein response may contribute to racial disparity in endocrine responsiveness in breast cancer. , 2015, , .		1
34	Abstract B2-09: A systems biology approach to understanding estrogen responsiveness in breast cancer cells using the MCF7 model. , 2015, , .		0
35	Abstract B1-23: Early growth response (EGR1) is a critical regulator of cellular metabolism and predicts increased responsiveness to antiestrogens in breast cancer. , 2015, , .		0
36	MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer. Molecular Cancer, 2014, 13, 239.	19.2	74

#	Article	IF	Citations
37	Glutamine metabolism and the unfolded protein response in MYC-driven breast cancer. Cancer & Metabolism, 2014, 2, .	5.0	1
38	Abstract 1634: A novel small molecule inhibitor of IRE1alpha reverses endocrine resistance in breast cancer cells. , 2014, , .		0
39	Abstract 679: Glutamine metabolism in MYC-driven antiestrogen resistant breast cancer cells confers metabolic flexibility through the unfolded protein response. , 2014, , .		0
40	Abstract C73: Differences in UPR signaling in ER+ breast cancer between African American and Caucasian women. , 2014, , .		0
41	Modelling the effect of GRP78 on anti-oestrogen sensitivity and resistance in breast cancer. Interface Focus, 2013, 3, 20130012.	3.0	26
42	Nitrosationâ€Dependent Caveolin 1ÂPhosphorylation, Ubiquitination, and Degradation and its Association with Idiopathic Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 816-830.	1.7	59
43	GX15-070 (Obatoclax) Induces Apoptosis and Inhibits Cathepsin D- and Lâ€“Mediated Autophagosomal Lysis in Antiestrogen-Resistant Breast Cancer Cells. Molecular Cancer Therapeutics, 2013, 12, 448-459.	4.1	49
44	A novel statistical approach to identify co-regulatory gene modules. , 2013, , .		2
45	Tyrosine-phosphorylated Caveolin-1 (Tyr-14) Increases Sensitivity to Paclitaxel by Inhibiting BCL2 and BCLxL Proteins via c-Jun N-terminal Kinase (JNK). Journal of Biological Chemistry, 2012, 287, 17682-17692.	3.4	58
46	Glucose-Regulated Protein 78 Controls Cross-talk between Apoptosis and Autophagy to Determine Antiestrogen Responsiveness. Cancer Research, 2012, 72, 3337-3349.	0.9	133
47	Endoplasmic Reticulum Stress, the Unfolded Protein Response, Autophagy, and the Integrated Regulation of Breast Cancer Cell Fate. Cancer Research, 2012, 72, 1321-1331.	0.9	183
48	Vitamin E succinate inhibits survivin and induces apoptosis in pancreatic cancer cells. Genes and Nutrition, 2012, 7, 83-89.	2.5	19
49	Autophagy and endocrine resistance in breast cancer. Expert Review of Anticancer Therapy, 2011, 11, 1283-1294.	2.4	137
50	Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer. Hormone Molecular Biology and Clinical Investigation, 2011, 5, 35-44.	0.7	49
51	The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer. International Journal of Breast Cancer, 2011, 2011, 1-9.	1.2	36
52	BCL2 and CASP8 regulation by NFâ€ÎºB differentially affect mitochondrial function and cell fate in antiestrogenâ€sensitive and â€resistant breast cancer cells. FASEB Journal, 2010, 24, 2040-2055.	0.5	76
53	Co-Inhibition of BCL-W and BCL2 Restores Antiestrogen Sensitivity through BECN1 and Promotes an Autophagy-Associated Necrosis. PLoS ONE, 2010, 5, e8604.	2.5	60
54	Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2009, 114, 8-20.	2.5	73

#	Article	IF	Citations
55	The role of X-box binding protein-1 in tumorigenicity. Drug News and Perspectives, 2009, 22, 241.	1.5	64
56	Caveolin-1 Tyrosine Phosphorylation Enhances Paclitaxel-mediated Cytotoxicity. Journal of Biological Chemistry, 2007, 282, 5934-5943.	3.4	61
57	Human Xâ€Box binding proteinâ€1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB Journal, 2007, 21, 4013-4027.	0.5	169
58	Tyrosine phosphorylationâ€dependence of caveolaeâ€mediated endocytosis. Journal of Cellular and Molecular Medicine, 2007, 11, 1239-1250.	3.6	96
59	Novel Mechanism of Endothelial Nitric Oxide Synthase Activation Mediated by Caveolae Internalization in Endothelial Cells. Circulation Research, 2006, 99, 870-877.	4.5	122